In their ongoing commitment to support fearless women, Secret Deodorant has created the Mean Stinks program; a supportive Facebook community that gives young women the courage to stand up to a stinky behavior – bullying. To help this cause, Secret is partnering with relatable role models—Amber Riley, best known as Mercedes on the hit FOX show Glee, and Rachel Simmons, nationally renowned relationship expert—to start a movement of “nice.” Together they are giving young women the strength to face challenges associated with bullying and mean behavior. Secret is also partnering with PACER’s National Bullying Prevention Center by donating a portion of proceeds from select Secret Clinical Strength purchases to it’s prevention efforts.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/meanstinks/50863/
CVS/pharmacy has kicked-off its ninth annual in-store fund raising campaign to support the fight against amyotrophic lateral sclerosis (ALS). Since 2002, CVS/pharmacy has partnered with the ALS Therapy Alliance (ATA) to help advance ALS research. To date, CVS/pharmacy has raised more than $19 million in its stores—a single $1 donation at a time—to support the funding of new clinical research with the aim of discovering a treatment or cure for this devastating disease. This year's campaign began on June 6 and runs through June 26.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cvs/44466/
Phenogen Sciences, Inc. [www.phenogensciences.com] today announced the immediate availability of BREVAGen™, a predictive risk test for the millions of women at above average risk of developing estrogen-receptor positive breast cancer. This first-in-class, scientifically-validated risk assessment test examines a woman’s clinical risk factors, such as her lifetime exposure to estrogen, combined with scientifically validated genetic markers to determine each patient’s personalized five-year and lifetime risk of developing breast cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58399-phenogen-sciences-brevagen-breast-cancer-risk-assessment-test-availability
Modern transcription isn’t just typing; it’s intelligent, integrated, and AI-accelerated. With MOS, every report is crafted through a hybrid workflow combining AI precision & expert transcriptionists, giving providers cleaner, faster, and more reliable clinical documentation.
Perfect for: physicians, clinics, hospitals, diagnostic centers, and multi-specialty groups.
